Obermatt
See Similar Stocks →

Belite Bio

NAQ:BLTE · US07782B1044
PharmaceuticalsSmall

360° View

49
Price/Sales4
Price/Earnings100
Price/Book1
Dividend Yield1
Revenue Growth—
Profit Growth5
Capital Growth96
TSR 52w100
Leverage97
Liquidity1
Refinancing26
Combined35
Analyst Opinions80
Pro Holdings65
Opinion Changes50
Market Pulse92

Profile

CountryTaiwan
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2018
Employees40
Websitebelitebio.com
ISINUS07782B1044
Last UpdateApr 2, 2026
Index & Theme
DiabetesChronic DiseasesOphthalmologyHepatologyEndocrinologyGastroenterologyBiotechnologyHealth CarePharmaceutical

Description

Belite Bio, Inc operates as a clinical stage biopharmaceutical drug development company. The company operates as a subsidiary of Lin Bioscience International Ltd. The company focused on advancing novel therapeutics targeting degenerative retinal dis…

Analysis

Belite Bio's 360° View rank of 49 places it below its peer average — better than 49% of its true peers.

It's a growth standout (83) and expensive versus peers (12). On safety it is highly leveraged (15), and the market shows strongly positive sentiment (91). Taken together, its Combined rank of 35 reads as below its peer average.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
4
—
—
—
Price/Earnings
100
—
—
—
Price/Book
1
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
12
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Belite Bio with its peers
Hansoh Pharmaceutical
HKG:3692
66
CountryHong Kong SAR China
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Gene One Life Science
KSC:011000
28
CountrySouth Korea
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Samil Pharmaceutical
KSC:000520
28
CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Clarity Pharmaceuticals
ASX:CU6
8
CountryAustralia
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Formosa Laboratories
TAI:4746
63
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Neuren Pharmaceuticals
ASX:NEU
29
CountryAustralia
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →